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Abstract
Background: To investigate the effectiveness and mechanism of 125I seed continuous low-dose-
rate irradiation on colonic cell line CL187 in vitro.
Methods: The CL187 cell line was exposed to radiation of 60Coγ ray at high dose rate of 2 Gy/
min and 125I seed at low dose rate of 2.77 cGy/h. Radiation responses to different doses and dose
rates were evaluated by colony-forming assay. Under 125I seed low dose rate irradiation, a total of
12 culture dishes were randomly divided into 4 groups: Control group, and 2, 5, and 10 Gy
irradiation groups. At 48 h after irradiation, apoptosis was detected by Annexin and Propidium
iodide (PI) staining. Cell cycle arrests were detected by PI staining. In order to investigate the
influence of low dose rate irradiation on the MAPK signal transduction, the expression changes of
epidermal growth factor receptor (EGFR) and Raf under continuous low dose rate irradiation
(CLDR) and/or EGFR monoclonal antibodies were determined by indirect immunofluorescence.
Results: The relative biological effect (RBE) for 125I seeds compared with 60Co γ ray was 1.41.
Apoptosis rates of CL187 cancer cells were 13.74% ± 1.63%, 32.58% ± 3.61%, and 46.27% ± 3.82%
after 2 Gy, 5 Gy, and 10 Gy irradiation, respectively; however, the control group apoptosis rate
was 1.67% ± 0.19%. G2/M cell cycle arrests of CL187 cancer cells were 42.59% ± 3.21%, 59.84% ±
4.96%, and 34.61% ± 2.79% after 2 Gy, 5 Gy, and 10 Gy irradiation, respectively; however, the
control group apoptosis rate was 26.44% ± 2.53%. P < 0.05 vs. control groups by Student's t-test
were found in every treated group both in apoptosis and in G2/M cell cycle arrest. After low dose
rate irradiation, EGFR and Raf expression increased, but when EGFR was blocked by a monoclonal
antibody, EGFR and Raf expression did not change.
Conclusion:  125I seeds resulted in more effective inhibition than 60Co  γ ray high dose rate
irradiation in CL187 cells. Apoptosis following G2/M cell cycle arrest was the main mechanism of
cell-killing effects under low dose rate irradiation. CLDR could influence the proliferation of cells
via MAPK signal transduction.
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Background
Because of its ability to offer high precision, little trauma,
strong lethality, and fewer complications [1-4], 125I radio-
active seed implantation has been widely applied in clin-
ical practice for tumor treatment, such as prostate
carcinoma [5], recurrent colorectal cancer [6-10], head
and neck carcinoma [11,12], and others [13-15]. How-
ever, radiobiological study of continuous low dose rate
irradiation (CLDR), and especially that which defines the
deep development of radioactive seed implantation and
its intersection with other subjects of tumor treatment,
has only recently been conducted [16,17]. Therefore, fur-
ther study on the basic radiobiology of continuous low
dose rate irradiation is necessary, particularly to provide
further clinical direction. In the present study, the CL187
colonic cell line was exposed to 125I seeds at low dose rate
irradiation, and killing effect of cells cultured in vitro were
observed to reveal the radiobilogical mechanism of 125I
radioactive seed irradiation.
Materials and methods
Reagents
Cell culture media was provided by the Zoology Institute
of the Chinese Academy of Sciences. Propidium iodide
(PI) and annexin V were purchased from Cell Signaling
Company (Cell Signaling Technology, Beverly, MA).
Phospho-P38 epidermal growth factor receptor (EGFR)
mAb (Alexa Fluor) and Phospho-raf mAb (Alexa Fluor)
were obtained from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). All other materials were obtained from the
Zoology Institute of the Chinese Academy of Sciences.
Cell lines and cell culture
The CL187 colonic cancer cell line was kindly provided by
the Beijing Institute for Cancer Research. It was main-
tained in RPMI1640 supplemented with 20 mM HEPES
(pH 7.4), 100 IU/mL penicillin, 100 mg/mL streptomy-
cin, 4 mM glutamine, and 10% heat-inactivated fetal
bovine serum (Hangzhou Sijiqing Biological Engineering
Materials Company, China) in a humidified atmosphere
of 95% air and 5% CO2 at 37°C.
125I seeds irradiation
We used our in-house developed in vitro iodine-125 seed
irradiation model shown in Figure 1[18]. The model con-
sists of a 3-mm thick polystyrene panel, with a lower seed
plaque layer and an upper cell culture plaque layer. In the
seed plaque, 14 seeds with the same activity were equally
spaced within recesses (4.5 mm × 0.8 mm) around a 35-
mm diameter (D) circumference. In the cell culture
plaque, the same recesses were made around a 35-mm D
circumference; its center was along the same vertical line
as that of the seed plaque, so that a 35-mm Petri dish
could be placed on it during the experiment. The height
(H) between the seed plaque and the bottom of Petri dish
was 12 mm, with a D/H ratio of 2.9. The purpose of this
design was to obtain a relatively homogeneous dose dis-
tribution at the bottom of the Petri dish. The polystyrene
assembly was enclosed by a 3-mm thick lead chamber
125I seed experiment irradiation pattern in vitro Figure 1
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with a vent-hole, so that during the study the whole
model could be kept in the incubator. The incubator
played a protective role by maintaining constant cell cul-
ture conditions. Model 6711 125I seeds were provided by
Ningbo Junan Pharmaceutical Technology Company,
China. The single seed activity used in this study was 92.5
MBq (2.5 mCi), corresponding initial dose rate in model
cells was 2.77 cGy/h. The dose uniformity of the irradia-
tion model in the cell plane was 1.34, which was similar
to other investigators' results [2]. The model was validated
using thermoluminescent dosimetry (TLD) measurement.
The absorbed dose for different exposure time in various
culture planes has also been measured and verified. The
exposure time for delivering doses of 100, 200, 400, 600,
800 and 1000 cGy are 36, 73.7, 154.6, 245.8, 345.1, 460.1
hours. Exponentially-growing CL187 cells in a tissue-cul-
ture flask (35 mm diameter) were irradiated using the
above model. The cells were subsequently incubated for
another 21 d at constant temperature and humidity. Irra-
diation was performed at the Zoology Institute of the Chi-
nese Academy of Sciences.
Clonogenic survival
Clonogenic survival was defined as the ability of cells to
maintain clonogenic capacity and to form colonies.
Briefly, cells in the control and irradiation groups were
exposed to different radiation dosages (0, 1, 2, 4, 6, 8, and
10 Gy). After incubation for 21 d, colonies were stained
with crystal violet and manually counted. The plating effi-
ciency (PE) and survival fraction (SF) were calculated as
follows: PE = (colony number/inoculating cell number) ×
100%. SF = PE (tested group)/PE (0-Gy group) × 100%. A
dose-survival curve was obtained for each experiment and
used for calculating several survival parameters. Parallel
samples were set at each irradiation dosage. The cell-sur-
vival curve was plotted with Origin 7.5 software, using the
equation: SF = 1 - (1 - e-D/D0)N. The multi-target, single-hit
model was applied to calculate cellular radiosensitivity
(mean lethal dose, D0), capacity for sublethal damage
repair (quasithreshold dose, Dq), and extrapolation
number (N). The D10values were used to calculate the rel-
ative biological effect (RBE).
Cell cycle and apoptosis analysis
Cells from the control and CLDR-treated groups were
exposed to different radiation dosages (0, 2, 5, and 10
Gy). Cells were harvested 48 h after irradiation. For detec-
tion of apoptotic cells, cells were trypsinized, acridine
orange stained, and determined under fluorescence
microscope. At the same time, cells were counted and
washed twice with cold PBS. Cells used for apoptosis tests
were stained with propidium iodide (PI) and annexin V
for 15 min in the dark. Cells used for cell-cycle testing
were stained with propidium iodide after ethanol fixation
and analyzed by fluorescence-activated cell sorting
(FACS) using Coulter EPICS and ModFit software (Verity
Software House, Topsham, MN). Each test was performed
3 times [19].
EGFR and Raf quantifications by FCM
Control and treated CL187 cells for EGFR and Raf quanti-
fications by FCM were harvested 24 h after 4 Gy irradia-
tion. Each test was performed 3 times. Cells used for tests
were stained with Phospho-P38 EGFR mAb (Alexa Fluor)
and Phospho-raf mAb (Alexa Fluor), and then analyzed
by FACScan using Coulter EPICS and ModFit software.
Each test was performed 3 times [20-22].
Statistical analysis
Data were plotted as means ± standard deviation. Stu-
dent's t test was used for comparisons. Differences were
considered significant at P < 0.05.
Results
Survival curve of CL187 cells after different dose rate 
irradiation
Data showed that cell-killing effects were related to dose
rate. The survival curve of CL187 cells after different dose
rate irradiation is shown in Figure 2. At the same dose, the
survival fractions of 125I seeds were always lower than
60Co γ ray (Table 1). The cloning efficiency of CL187 was
between 70% and 90%. Radiobiological parameters of
Dose-survival curves of CL187 cells after high and low dose  rate irradiation Figure 2
Dose-survival curves of CL187 cells after high and 
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high dose rate irradiation treated CL187 cells were D0 =
1.85, Dq = 0.35, and N = 1.55, while those of 125I seed low
dose rate irradiation cells were D0 = 1.32, Dq = 0.14, and
N = 1.28. In the present study, RBE = D10 
60Co/D10
125I =
4.23/3.01 = 1.41. The data presented herein suggested that
the biological effect of 125I seed irradiation was stronger
than that of 60Co γ ray (t = 2.578, P < 0.05).
Low dose rate irradiation-induced apoptosis and cell cycle 
arrest
Cells were stained by acridine orange and observed under
fluorescence microscopy; typical morphological features
of apoptotic cells appeared after 5 Gy low dose rate irradi-
ation (Fig. 3). FCM analysis showed that under low dose
rate irradiation, apoptosis and G2/M cell cycle arrest
increased slightly at 2 Gy, the peak appeared at 5 Gy, and
the ratio was also high at 10 Gy (Table 2) but lower than
that at 5 Gy. Furthermore, G2/M cell cycle arrest and apop-
tosis walked together along with the dose change (r =
0.918, P < 0.01, Fig. 4). Quantitative measurements of
apoptotic cell death by FCM in CL187 cells sufficiently
indicated that apoptosis is an important mechanism of
low dose rate irradiation inhibition of CL187 cell prolifer-
ation.
Expression changes of EGFR and Raf in CL187 cells after 
irradiation and/or EGFR monoclonal antibody treatment
Under low dose rate irradiation, expression of EGFR
(74.27 ± 5.63%) and Raf (53.84 ± 2.31%) was signifi-
cantly higher than in the control group (Fig. 5 and Table
3). After signal transduction was blocked, expression of
EGFR (2.07 ± 0.31%) and Raf (13.74 ± 1.82%) did not
show detectable change after low dose rate irradiation
(Fig. 5 and Table 3).
Discussion
Low-energy radioactive seed interstitial implantation has
resulted in positive clinical treatment of many tumors pre-
viously radioresistant to high dose rate irradiation. This
may be due to different radiobiological mechanisms
between low and high dose rate irradiation. Nevertheless,
compared with springing up of radioactive seeds intersti-
tial implantation, fundamental research on this topic is
notably absent, and the radiobiological mechanism of 125I
seed low dose rate irradiation remains unclear.
As classic methods of appraising killing efficacy of irradi-
ation, cell proliferation and clonic assays were used in the
experiment. High dose rate irradiation killed tumor cells,
but simultaneously induced radioresistance. However, the
dose survival curve of 125I seed continuous low dose rate
irradiation had no significant shoulder region, and SF was
lower than 60Co γ ray high dose rate irradiation. From the
radiobiological parameter results, we also observed that
125I continuous low dose rate irradiation showed great
advantages relative to high dose rate irradiation. Although
RBE could be affected by many factors, such as cell line
and dose rate, most studies have shown that the RBE of
125I was between 1.3 and 1.5. The present results are con-
sistent with previous reports [24-27].
Our results indicated that apoptosis may play a central
role regarding the observed killing effects when cells were
exposed to 125I seed low dose rate irradiation [28,29].
Prior studies have suggested that radiosensitivity is cell
cycle dependent, and cells in the G2/M phase could be
more radioresponsive [30]. These results suggest that
CLDR may enhance radiosensitivity by inducing accumu-
lation of cells in a more radiosensitive cell cycle phase
(G2/M) [31,32]. The apoptosis index of 10 Gy was lower
than that of 5 Gy; two possibilities for this occurrence are:
(a) Early-apoptotic cells disintegrated within the exposure
time of 10 Gy, and could not be detected by FCM; and (b)
Low dose rate irradiation only delayed the cell cycle, but
could not completely block the cell cycle. Overshoot early
irradiation, cells changed to be more radioresistant.
Therefore, the apoptotic cells under 10 Gy were fewer than
those under 5 Gy. Similarly, G2/M arrest also declined
under 10 Gy [33].
Our results indicated that the up-regulation of Raf expres-
sion correlated well with an increase in the level of EGFR
expression after 125I seed irradiation [34-37]. It is sug-
gested that the expression changes were all induced by
CLDR. It is essential to prove that CLDR functioned via
MAPK signal transduction. When the signal transduction
Table 1: Survival fraction of different dose rate irradiation in CL187 cell line (%,   ± s)
Irradiation dose (Gy)
12 4 6 8 1 0
Survival fraction
60Co 73 ± 22 49 ± 11 17 ± 5.2 5.7 ± 2.1 1.8 ± 0.19 0.74 ± 0.21
125I5 5  ±  1 8 a 28 ± 10b 5.2 ± 2.7c 1.3 ± 0.25d 0.33 ± 0.12e 0.08 ± 0.03f
Compared with 60Co group, t = 8.03, aP < 0.05; t = 4.85, bP < 0.05; t = 13.69, cP < 0.01; t = 11.43, dP < 0.01; t = 4.76, eP < 0.05; and t = 4.62, fP < 
0.05.
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Apoptosis of 125I low dose rate irradiation-treated CL187 cells Figure 3
Apoptosis of 125I low dose rate irradiation-treated CL187 cells. CL187 cells were stained with acridine orange, and 
determined under fluorescence microscope. There were no apoptotic cells in control groups (A), but typical morphological 
features of apoptosis appeared after 5 Gy CLDR irradiation (B). The apoptotic rates were detected by flow cytometry. In 2 Gy 
(D), 5 Gy (E), and 10 Gy (F) groups, the CL187 cells had higher apoptosis rates when compared with control groups (C). Con-
crete data see table 3. One of three experiments is shown. P < 0.05 vs. control group were found in every treated groups.Journal of Experimental & Clinical Cancer Research 2009, 28:12 http://www.jeccr.com/content/28/1/12
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Effect of 125I low dose rate irradiation on the cell cycle in CL187 cells Figure 4
Effect of 125I low dose rate irradiation on the cell cycle in CL187 cells. Flow cytometry analysis revealed that the G2/
M phase increased by 2 Gy (B)125I irradiation dose as compared with untreated control cells (A). After 5 Gy irradiation (C), a 
sharp increase in the fraction of cells in the G2/M phase was observed. The result in 10 Gy irradiation groups (D) was lower 
than that in group C, but sustained at a relatively high level. Compared with untreated control cells, P < 0.05 were found in all 
of the treated groups.Journal of Experimental & Clinical Cancer Research 2009, 28:12 http://www.jeccr.com/content/28/1/12
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was blocked by the EGFR monoclonal antibody, no obvi-
ous change in Raf expression occurred after 125I seed irra-
diation. It was proved that the necessary conditions were
also sufficient [38,39]. These results formed the basis for
combining CLDR with EGFR tyrosine kinase inhibitors in
clinical practice [40,41,22].
In summary, our study provides a beneficial exploration
of radiobiology of continuous low dose rate irradiation.
Although many issues remain to be addressed, we believe
that, with further development of fundamental research,
application of 125I radioactive seed implantation in clini-
cal practice will continue to be improved.
Table 2: Apoptosis index and cell cycle distribution after 125I low 
dose rate irradiation (%,   ± s).
Apoptosis G0/G1 SG 2/M
Control 1.67 ± 0.19 64.94 ± 5.87 8.62 ± 0.59 26.44 ± 2.53
2 Gy 13.74 ± 1.63a 54.14 ± 3.16 11.25 ± 1.34 34.61 ± 2.79d
5 Gy 46.27 ± 3.82b 26.60 ± 2.82 13.56 ± 1.68 59.84 ± 4.96e
10 Gy 32.58 ± 3.61c 41.69 ± 4.58 15.72 ± 2.29 42.59 ± 3.21f
Compared with control group (apoptosis), t = 8.377, aP < 0.05; t = 
36.44, bP < 0.01; and t = 27.35, cP < 0.01. Compared with control 
group (G2/M arrests), t = 30.81, dP < 0.05; t = 23.98, dP < 0.05; and t 
= 26.3, eP < 0.05.
x
EGFR and Raf expression changes in CL187 cells after 125I irradiation and/or Anti-EGFR mAb Figure 5
EGFR and Raf expression changes in CL187 cells after 125I irradiation and/or Anti-EGFR mAb. CLDR could influ-
ence the proliferation of cells via MAPK signal transduction. One representive of two experiments is shown.Journal of Experimental & Clinical Cancer Research 2009, 28:12 http://www.jeccr.com/content/28/1/12
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